本文由小咖机器人翻译整理

期刊来源：Nat Med

原文链接：https://doi.org/10.1038/s41591-023-02784-9

摘要内容如下：

近年来，对量化生物老化的生物标记物（特别是基于“组学”的生物标记物）的研究得到了加强。这些生物标记物可以预测与衰老相关的结果，并可以作为评估促进健康老龄化和长寿的干预措施的替代终点。然而，对于衰老的生物标志物在应用于临床之前应该如何验证，目前还没有达成共识。在此，我们回顾了目前在人群研究中评估衰老生物标志物的预测有效性的努力，讨论了可比性和可推广性的挑战，并提供了促进衰老生物标志物未来验证的建议。最后，我们讨论了系统验证如何加速衰老生物标志物的临床转化及其在老年治疗临床试验中的应用。

英文原文如下：

Abstracts

The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。

现在购买可享受最大优惠（买一年送三个月，买两年送一年），2024年2月10日起将不再享有该优惠。